{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:49:16Z","timestamp":1791942556668,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCV-infected patients with severe renal failure [including haemodialysis (HD) patients].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty patients (36 males, mean age \u00b1 standard deviation 60.5 \u00b1 7.5 years) with chronic HCV infection (G1: 28\/56%, cirrhosis: 27\/54%) and severe renal failure [i.e. MDRD estimated glomerular filtration rate (eGFR) &amp;lt;35 mL\/min], including 35 on HD, were enrolled. Antiviral treatment consisted of SOF\/ribavirin (RBV) (n = 7), SOF\/RBV\/pegylated interferon (n = 2), SOF\/daclatasvir \u00b1 RBV (n = 30) or SOF\/simeprevir \u00b1 RBV (n = 11) for 12 or 24 weeks. A reduced dose of SOF (400 mg three times a week or 400 mg every other day) was given to all HD patients. Initial dose of RBV (n = 12) ranged from 400 to 4200 mg\/week.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On an intent-to-treat-based analysis, sustained virological response rate was 86% at 12 weeks. During therapy, haemoglobin levels were not significantly modified, but recombinant erythropoietin (rEPO) dose significantly increased in patients treated with RBV. Two patients (4%) required blood transfusion. No patient had treatment discontinuation due to side effects. Dose of RBV was reduced in two patients (16.7%) during antiviral therapy. Dose of SOF was reduced in two non-HD patients because of side effects. In non-HD patients, median eGFR was not significantly modified during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results strongly suggest that SOF-based antiviral therapy, with a reduced dose of SOF, is safe and effective for the treatment of HCV patients with ESRD, including HD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfw348","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T15:06:19Z","timestamp":1476716779000},"page":"2065-2071","source":"Crossref","is-referenced-by-count":16,"title":["Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure"],"prefix":"10.1093","volume":"32","author":[{"given":"J\u00e9r\u00f4me","family":"Dumortier","sequence":"first","affiliation":[{"name":"Edouard Herriot Hospital and University of Lyon 1, Hospices Civils de Lyon Department of Digestive Diseases , , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bailly","sequence":"additional","affiliation":[{"name":"Croix-Rousse Hospital, Hospices Civils de Lyon Department of Hepatogastroenterology , , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Philippe","family":"Pageaux","sequence":"additional","affiliation":[{"name":"Saint Eloi University Hospital, University of Montpellier Department of Hepatogastroenterology and Liver Transplantation , , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"additional","affiliation":[{"name":"Cochin Hospital, APHP, INSERM UMS-20 Institut Pasteur Department of Hepatology , , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Radenne","sequence":"additional","affiliation":[{"name":"Croix-Rousse Hospital, Hospices Civils de Lyon Department of Hepatogastroenterology , , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Habersetzer","sequence":"additional","affiliation":[{"name":"P\u00f4le H\u00e9pato-digestif, IHU Strasbourg, INSERM U1110, University of Strasbourg Hepatology Unit , , Strasbourg ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Gagnieu","sequence":"additional","affiliation":[{"name":"Edouard Herriot Hospital, Hospices Civils de Lyon Department of Pharmacology , , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Didier","family":"Grang\u00e9","sequence":"additional","affiliation":[{"name":"Tenon Hospital Department of Hepatogastroenterology , , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[{"name":"Dijon University Hospital Department of Hepatogastroenterology , , Dijon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Guillaud","sequence":"additional","affiliation":[{"name":"Edouard Herriot Hospital and University of Lyon 1, Hospices Civils de Lyon Department of Digestive Diseases , , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[{"name":"Toulouse University Hospital, Universit\u00e9 Paul Sabatier, INSERM U1043, IFR\u2013BMT Department of Nephrology and Organ Transplantation , , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[{"name":"CHU Purpan, UMR 152, IRD Toulouse 3 University Internal Medicine-Digestive Department , , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[{"name":"CHU A Michallon, Universit\u00e9 Grenoble Alpes Department of Hepatology and Gastroenterology and INSERM U823 , , Grenoble ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,19]]},"reference":[{"key":"2025102312475220400_GFW348C1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/tri.12360","article-title":"Hepatitis C virus infection in end-stage renal disease and kidney transplantation","volume":"27","author":"Burra","year":"2014","journal-title":"Transpl Int"},{"key":"2025102312475220400_GFW348C2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2893.2007.00853.x","article-title":"Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis","volume":"14","author":"Butt","year":"2007","journal-title":"J Viral Hepat"},{"key":"2025102312475220400_GFW348C3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"2025102312475220400_GFW348C4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation"},{"key":"2025102312475220400_GFW348C5","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","article-title":"Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy","volume":"11","author":"Nakayama","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2025102312475220400_GFW348C6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/13543784.2013.775246","article-title":"Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection","volume":"22","author":"Herbst","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2025102312475220400_GFW348C7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations","volume":"53","author":"de Kanter","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2025102312475220400_GFW348C8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2025102312475220400_GFW348C9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FTD.0b013e3181a665e3","article-title":"Feasibility of ribavirin therapeutic drug monitoring in hepatitis C","volume":"31","author":"Sauvage","year":"2009","journal-title":"Ther Drug Monit"},{"key":"2025102312475220400_GFW348C10","article-title":"Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics","volume":"54","author":"Denning","year":"2011","journal-title":"Hepatology"},{"key":"2025102312475220400_GFW348C11","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1365-2893.2010.01405.x","article-title":"Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials","volume":"18","author":"Fabrizi","year":"2011","journal-title":"J Viral Hepat"},{"key":"2025102312475220400_GFW348C12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2012.10.009","article-title":"Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?","volume":"56","author":"Dumortier","year":"2013","journal-title":"J Clin Virol"},{"key":"2025102312475220400_GFW348C13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"2025102312475220400_GFW348C14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"2025102312475220400_GFW348C15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Kalyan Ram","year":"2015","journal-title":"J Hepatol"},{"key":"2025102312475220400_GFW348C16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/gast.2002.36610","article-title":"Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection","volume":"123","author":"Alric","year":"2002","journal-title":"Gastroenterology"},{"key":"2025102312475220400_GFW348C17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0272-6386(97)90345-0","article-title":"The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients","volume":"29","author":"Knoll","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2025102312475220400_GFW348C18","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","article-title":"Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group","volume":"53","author":"Pereira","year":"1998","journal-title":"Kidney Int"},{"key":"2025102312475220400_GFW348C19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"2025102312475220400_GFW348C20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0272-6386(98)70027-7","article-title":"Risk of death among chronic dialysis patients infected with hepatitis C virus","volume":"32","author":"Stehman-Breen","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025102312475220400_GFW348C21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","article-title":"Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation","volume":"14","author":"Kamar","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025102312475220400_GFW348C22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients","volume":"23","author":"Nicot","year":"2010","journal-title":"Transpl Int"},{"key":"2025102312475220400_GFW348C23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","article-title":"Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation","volume":"78","author":"Bruchfeld","year":"2004","journal-title":"Transplantation"},{"key":"2025102312475220400_GFW348C24","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"2025102312475220400_GFW348C25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"2025102312475220400_GFW348C26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007890-199901270-00015","article-title":"Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years","volume":"67","author":"Younossi","year":"1999","journal-title":"Transplantation"},{"issue":"(Suppl 8)","key":"2025102312475220400_GFW348C27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndt\/15.suppl_8.65","article-title":"Glomerulonephritis associated with hepatitis C virus infection after renal transplantation","volume":"15","author":"Cruzado","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312475220400_GFW348C28","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1097\/01.ASN.0000145896.16153.43","article-title":"Hepatitis C, acute humoral rejection, and renal allograft survival","volume":"15","author":"Forman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025102312475220400_GFW348C29","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025102312475220400_GFW348C30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/ndt\/gfm011","article-title":"Diabetes mellitus after kidney transplantation: a French multicentre observational study","volume":"22","author":"Kamar","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312475220400_GFW348C31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1600-6143.2005.00918.x","article-title":"Natural history of hepatitis C virus-related liver fibrosis after renal transplantation","volume":"5","author":"Kamar","year":"2005","journal-title":"Am J Transplant"},{"key":"2025102312475220400_GFW348C32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/17.1.129","article-title":"Severe evolution of chronic hepatitis C in renal transplantation: a case control study","volume":"17","author":"Zylberberg","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312475220400_GFW348C33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2015.1114099","article-title":"Paritaprevir\/ritonavir\/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection","volume":"16","author":"Cheng","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2025102312475220400_GFW348C34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"2025102312475220400_GFW348C35","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"2025102312475220400_GFW348C36","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/12\/2065\/22144353\/gfw348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/12\/2065\/22144353\/gfw348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:11Z","timestamp":1761238091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/12\/2065\/2327317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,19]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,10,19]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw348","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12]]},"published":{"date-parts":[[2016,10,19]]}}}